Vanguard Investments Australia
LBRX

Vanguard Investments Australia’s LB Pharmaceuticals LBRX Stock Holding History

Vanguard Investments Australia’s Portfolio LBRX Stock Details LBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$166K Buy
+5,105
New +$150K ﹤0.01% 2186

Other funds holding LBRX

DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
NCM
Nantahala Capital Management New Canaan, Connecticut $3B AUM 119.43% 1-Year Est. Return

Vanguard Investments Australia's LBRX Position: Q2 2026 in Review

Vanguard Investments Australia opened a new position in LB Pharmaceuticals (LBRX) in Q2 2026: 5,105 shares worth $166K. The stake represents ﹤0.01% of the portfolio and ranks #2186 among its holdings.

106 funds tracked by Wall St. Rank hold LBRX as of Q2 2026.

  • Vanguard Investments Australia held 5,105 shares of LB Pharmaceuticals worth $166K as of Q2 2026.
  • LB Pharmaceuticals was a new Vanguard Investments Australia position in Q2 2026.
  • LB Pharmaceuticals made up ﹤0.01% of Vanguard Investments Australia's portfolio in Q2 2026, its #2186 holding.
  • 106 funds tracked by Wall St. Rank held LB Pharmaceuticals as of Q2 2026.

Based on Vanguard Investments Australia's 13F filing for Q2 2026, filed 13 Aug 2026.